Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE)

Abstract

ObjectivesPatients with advanced ankylosing spondylitis (AS) experience disability because of reduced spinal mobility and pulmonary function impairment. This placebo-controlled study evaluated the effect of etanercept (ETN) in patients with advanced AS.MethodsA multicentre randomised double-blind placebo-controlled trial of 12 weeks' duration was performed. Patients had definite (modified New York criteria), active (Bath AS Disease Activity Index (BASDAI) ≥40), severe (radiological intervertebral bridges) AS refractory to non-steroidal anti-inflammatory drugs and were antitumour necrosis factor naive. They were treated with ETN 50 mg once weekly or identical placebo (PBO).ResultsOf the 95 patients screened, 82 were randomised to receive ETN (n=39) or PBO (n=43). At baseline the disease was active (mean BASDAI 61.0±13.4, C reactive protein (CRP) 20.7±25.5 mg/l) and severe (mean Bath AS Metrology Index (BASMI) 5.7±1.3, mSASSS 36.5±20.5); forced pulmonary vital capacity (FVC) was 3.3±0.7 l. Improvement in BASDAI (normalised net incremental area under the curve between baseline and week 12, primary end point) was significantly greater in the ETN group than in the PBO group (−19.8±16.5 vs −11.0±16.4, p=0.019). Moreover, at week 12, ETN gave better results than PBO for the BASDAI (−26.4±19.7 vs −14.4±19.7; p=0.008), total back pain (−29.2±24.0 vs −14.9±24.0; p=0.010), BASFI (−21.7±17.6 vs −10.1±17.6; p=0.004), BASMI (−0.6±0.6 vs −0.2±0.6; p=0.011), CRP level (−15.7±14.2 vs −1.3±14.2; p<0.001) and FVC (+160±280 ml vs −20±280 ml; p=0.006).ConclusionsETN has short-term efficacy for patients with advanced AS, as was previously reported for less advanced disease. The efficacy is observed for the main symptoms (pain) and on markers of inflammation (CRP), as well as disease severity in terms of spinal mobility and pulmonary function.

Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation

“…For three of the 24 trials no information on AEs was available. 55,56,74 Several trials provided AE data only at time points after which placebo patients may have switched to receive an anti-TNF (so true placebo comparisons were not available).…”

Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases

“…Most studies required participants to have failed at least one NSAID before inclusion. Earlier trials also generally excluded patients with complete boney fusion (ankylosis) of the spine, apart from the trial by Dougados et al (2011), which specifically tested the effect in patients with moderate to severe existing ankylosis and new bone formation.…”

Treatment of ankylosing spondylitis with biologics and targeted physical therapy

“…__Demonstrated by our patients' parameters, the inhibition of inflammation led to lower pain intensity and disease activity, better physical conditions and functionality. In the case of 55 patients, moderate pain, larger MSI and chest expansion were observed, showing decreased BASFI and BASDAI values [23,24,25,26,27]. The limitation of this study part is its retrospective character.…”